Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPRXNASDAQ:OBSVNASDAQ:PBMNASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPRXKiora Pharmaceuticals$2.82-2.1%$3.14$2.51▼$4.86$8.77M-0.66133,534 shs15,700 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs2,900 shsPBMPsyence Biomedical$5.14-3.7%$4.62$2.92▼$699.19$3.04M0.21112,634 shs28,821 shsSNSESensei Biotherapeutics$8.85+3.1%$7.21$5.00▼$17.40$10.81M0.2645,277 shs6,436 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPRXKiora Pharmaceuticals-2.08%-8.14%-7.24%+0.36%-35.17%OBSVObsEva0.00%0.00%0.00%0.00%0.00%PBMPsyence Biomedical-3.66%+1.68%+14.37%+9.46%-97.31%SNSESensei Biotherapeutics+3.15%+4.49%+44.14%+20.90%-25.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKPRXKiora Pharmaceuticals2.71 of 5 stars3.52.00.00.03.31.70.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence Biomedical1.6745 of 5 stars0.05.00.00.02.71.70.6SNSESensei Biotherapeutics4.8408 of 5 stars3.75.00.04.83.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPRXKiora Pharmaceuticals 3.00Buy$10.00254.61% UpsideOBSVObsEva 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$90.00916.95% UpsideCurrent Analyst Ratings BreakdownLatest PBM, KPRX, OBSV, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.005/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPRXKiora Pharmaceuticals$16.02M0.54$1.22 per share2.32$8.58 per share0.33OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00PBMPsyence BiomedicalN/AN/A$1.72 per share2.99$11.80 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APBMPsyence Biomedical$1.01MN/A0.00∞N/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)Latest PBM, KPRX, OBSV, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$4.20-$5.40-$1.20-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPRXKiora PharmaceuticalsN/A5.145.14OBSVObsEvaN/A0.610.61PBMPsyence BiomedicalN/A11.0411.04SNSESensei BiotherapeuticsN/A6.826.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPRXKiora Pharmaceuticals76.97%OBSVObsEva17.52%PBMPsyence Biomedical77.44%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipKPRXKiora Pharmaceuticals0.05%OBSVObsEva14.40%PBMPsyence Biomedical3.60%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePBMPsyence BiomedicalN/A570,000549,000N/ASNSESensei Biotherapeutics401.26 million968,000Not OptionablePBM, KPRX, OBSV, and SNSE HeadlinesRecent News About These CompaniesSensei Biotherapeutics to execute 1-for-20 reverse stock splitJune 13, 2025 | kalkinemedia.comKSensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitJune 13, 2025 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 28, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 28, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comBSensei Biotherapeutics provides update, highlights key upcoming milestonesJanuary 9, 2025 | markets.businessinsider.comPromising Outlook for Sensei Biotherapeutics: Buy Rating Backed by SNS-101 Development and Financial ProjectionsJanuary 9, 2025 | markets.businessinsider.comSensei Biotherapeutics Inc (SNSE) Stock Trading RecapJanuary 9, 2025 | bovnews.comBSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 8, 2025 | globenewswire.comSensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare ConferenceNovember 28, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBM, KPRX, OBSV, and SNSE Company DescriptionsKiora Pharmaceuticals NASDAQ:KPRX$2.82 -0.06 (-2.08%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.88 +0.06 (+2.30%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Psyence Biomedical NASDAQ:PBM$5.14 -0.20 (-3.66%) Closing price 07/1/2025 03:50 PM EasternExtended Trading$5.19 +0.05 (+1.05%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Sensei Biotherapeutics NASDAQ:SNSE$8.85 +0.27 (+3.15%) Closing price 07/1/2025 03:52 PM EasternExtended Trading$8.87 +0.02 (+0.27%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
